Targeting PDE4 to modulate the cAMP pathway presents a therapeutic approach for treating a range of chronic inflammatory conditions and potentially some cancers, aiming to lessen inflammation and curb tumor development. The gene discussed is PDE4A; the disease is neoplasm.